|
Abbreviated name: AMY
Compound class:
Endogenous peptide in human, mouse or rat
Comment: Amylin acts as an appetite suppressor. Novo Nordisk have a long-acting amylin mimetic (AM833, NNC0174-0833) in clinical trials with and without semaglutide. AM833 is intended as a treatment for obesity. In the trials it is administered subcutaneously, once-weekly. Preliminary (and as yet unpublished) results from a Phase 2 trial as monotherapy demonstrated weight loss of 10.8% at week 26, meeting the study's primary endpoint (Novo Nordisk press release 18 Jun 2020).
Species: Human
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
| References |
|
1. Gingell JJ, Burns ER, Hay DL. (2014)
Activity of pramlintide, rat and human amylin but not Aβ1-42 at human amylin receptors. Endocrinology, 155 (1): 21-6. [PMID:24169554] |
|
2. Muff R, Bühlmann N, Fischer JA, Born W. (1999)
An amylin receptor is revealed following co-transfection of a calcitonin receptor with receptor activity modifying proteins-1 or -3. Endocrinology, 140 (6): 2924-7. [PMID:10342886] |
|
3. Zimmermann U, Fluehmann B, Born W, Fischer JA, Muff R. (1997)
Coexistence of novel amylin-binding sites with calcitonin receptors in human breast carcinoma MCF-7 cells. J Endocrinol, 155 (3): 423-31. [PMID:9487987] |
